Fracture risk a class effect of thiazolidinediones in womenBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39154.373889.DB (Published 15 March 2007) Cite this as: BMJ 2007;334:551
- Robert Short
Treatment with thiazolidinediones (glitazones) for type 2 diabetes has been found to increase the risk of fractures in women. Pioglitazone has now joined rosiglitazone, as the subject of a US Food and Drug Administration alert for fracture risk.
Takeda, the makers of pioglitazone (contained in Actos, Actosplusmet, and Duetact), and GlaxoSmithKline, the makers of rosiglitazone (contained in Avandia and Avandamet), have contacted US healthcare professionals setting out the evidence on fracture risk and recommending that they consider this risk when starting or treating women with type 2 diabetes with these agents.
The statement on pioglitazone …